Article Text

Cardiovascular highlights from non-cardiology journals
  1. Steven M Bradley, JournalScan Editor

Statistics from

Pharmacogenetic warfarin dosing shows marginal to no benefit

The inter-individual variation in warfarin dosing requirements and narrow therapeutic index for anticoagulation necessitates a personalized dosing regimen. Variation in dosing requirements are in part explained by genetic polymorphism in CYP (involved in warfarin metabolism) and VKOR (a warfarin target) genes. A dosing strategy informed by these polymorphism may hold promise to improve anticoagulation control. In three large randomized trials of similar design, a sophisticated pharmacogenetic approach to warfarin initiation was compared with standard care. All three studies used the percentage of time in therapeutic range as the primary end-point. None of the studies were powered to assess bleeding complications. A genotype-guided dosing approach failed to demonstrate improvements in anticoagulation control for the two largest studies. In the …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.